Galapagos NV Stock Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
Sales 2024 * | 319M 343M | Sales 2025 * | 297M 320M | Capitalization | 1.78B 1.91B |
---|---|---|---|---|---|
Net income 2024 * | -6M -6.46M | Net income 2025 * | -65M -69.95M | EV / Sales 2024 * | -4.99 x |
Net cash position 2024 * | 3.37B 3.62B | Net cash position 2025 * | 2.98B 3.21B | EV / Sales 2025 * | -4.06 x |
P/E ratio 2024 * |
-37.4
x | P/E ratio 2025 * |
-17.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |